Thyroid Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
Thyroid carcinomas are relatively
uncommon tumors. They include disease types that range from indolent behaviour,
such as papillary carcinomas, to fulminant and lethal anaplastic disease. It
originates from 2 types of thyroid endocrine cells; Follicular thyroid and
parafollicular cells. This accounts for >90% of thyroid malignancies and
including papillary thyroid cancer (PTC), follicular thyroid cancer (FTC),
poorly differentiated thyroid cancer (PDTC), and anaplastic thyroid cancer
(ATC). Of note, PTC and FTC are classified as differentiated thyroid cancer
(DTC). There are two classical signalling pathways, the MAPK and the PI3K-AKT
pathways. Both pathways are coupled to the receptor tyrosine kinase (RTK) at
the cell membrane, which transduces an extracellular growth stimulus that
prompts downstream intracellular signalling. The MAPK pathway has a fundamental
role in regulating cell proliferation, differentiation, apoptosis, and survival
and has been linked to tumorigenesis when disrupted. Once RTK is activated by
an extracellular signal, downstream activation of RAS, followed by BRAF, MEK,
and then ERK occurs. ERK enters the nucleus to induce tumour-promoting genes
and downregulate tumor suppressor genes and thyroid iodide-handling genes.
·
The incidence of Thyroid carcinomas ranges
from 8 to 17 cases per 100,000 population in the USA.
Thelansis’s “Thyroid Cancer Market
Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2021 To 2032" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Thyroid
Cancer treatment modalities options for eight major markets (USA, Germany,
France, Italy, Spain, UK, Japan, and China).
KOLs insights
of Thyroid Cancer across 8 MM market from the centre of Excellence/ Public/
Private hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Thyroid Cancer Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment